Published in Oncologist on February 01, 2005
Deciphering cellular states of innate tumor drug responses. Genome Biol (2006) 1.83
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res (2007) 1.36
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer (2008) 1.24
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer (2008) 1.07
Prospective health care: the second transformation of medicine. Genome Biol (2006) 1.07
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn (2006) 0.99
Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med (2006) 0.90
Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther (2012) 0.88
Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res (2012) 0.87
Using Drosophila melanogaster to identify chemotherapy toxicity genes. Genetics (2014) 0.87
The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans. G3 (Bethesda) (2013) 0.86
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res (2010) 0.83
Pharmacogenomics in early-phase clinical development. Pharmacogenomics (2013) 0.83
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol (2007) 0.82
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster. Pharmacogenet Genomics (2012) 0.81
Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol (2014) 0.79
Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Ann Transl Med (2014) 0.78
Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) (2017) 0.76
Gender specific tumour pharmacology--from kinetics to genetics. Wien Med Wochenschr (2006) 0.76
Sex-specific aspects of tumor therapy. Radiat Environ Biophys (2009) 0.76
TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol (2005) 0.76
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol (2017) 0.75
Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy. Onco Targets Ther (2017) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics (2003) 2.03
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol (2006) 1.98
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev (2002) 1.86
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther (2005) 1.81
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol (2003) 1.80
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther (2002) 1.79
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol (2008) 1.67
Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res (2008) 1.66
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem (2005) 1.56
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol (2007) 1.56
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther (2003) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology (2005) 1.50
Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. Am J Hypertens (2006) 1.48
Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics (2004) 1.47
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res (2008) 1.44
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem (2003) 1.44
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol (2013) 1.39
Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther (2006) 1.37
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res (2008) 1.36
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP (2012) 1.32
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther (2003) 1.31
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics (2011) 1.24
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Pharmacogenomics of the OATP and OAT families. Pharmacogenomics (2004) 1.21
Nuclear receptors and drug disposition gene regulation. J Pharm Sci (2005) 1.21
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther (2003) 1.16
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res (2002) 1.16
P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res (2004) 1.15
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol (2010) 1.15
Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest (2005) 1.14
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther (2005) 1.13
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat (2013) 1.13
Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol (2004) 1.12
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther (2003) 1.10
TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers (2008) 1.09
Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 1.09
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res (2006) 1.08
Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev (2008) 1.07
Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther (2006) 1.07
Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos (2005) 1.05
Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res (2009) 1.04
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol (2002) 1.04
Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol (2003) 1.04
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res (2008) 1.04
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics (2006) 1.03
Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol (2002) 1.02
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos (2007) 1.02
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr (2003) 1.01
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom (2008) 1.00
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer (2009) 1.00
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs (2008) 0.98
"Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther (2003) 0.97
Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res (2014) 0.95
A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm (2012) 0.95
The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res (2011) 0.95
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer (2011) 0.95
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet (2013) 0.95
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos (2010) 0.94
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther (2006) 0.94
Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev (2002) 0.94
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol (2007) 0.94
Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther (2005) 0.94
Alpha 1A-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther (2004) 0.93
Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics (2010) 0.93
The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem (2003) 0.92
Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol (2002) 0.92